Provention Bio, Inc.
DelistedCIK 1695357fmd_08DFGZ3K4GPBYBC53EQW1RRRRHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 02, 2016 to Dec 31, 2022, 24 periods
Latest annual · FY2022
Millions- Total revenues
- 13
- Operating income
- (128)
- Net income
- (114)
- Free cash flow
- (76)
Latest quarter · Q4 FY2022
Millions- Total revenues
- 11
- Operating income
- (40)
- Net income
- (33)
- Free cash flow
- (8)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- n/m
- Revenue, 5 yearsFY2017 to FY2022
- n/m
- Net income, 5 yearsFY2017 to FY2022
- n/m
Provention Bio, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $12.9 million | $1.4 million | +824.4% | 10-K 2023-03-29 · proof |
| Operating income | -$128.2 million | -$115.6 million | 10-K 2023-03-29 · proof | |
| Net income | -$113.6 million | -$114.4 million | 10-K 2023-03-29 · proof | |
| Cash from operating activities | -$75.4 million | -$95.4 million | 10-K 2023-03-29 · proof | |
| Free cash flow | -$76.2 million | -$96.3 million | 10-K 2023-03-29 · proof | |
| Total assets | $236.9 million | $135.6 million | +74.6% | 10-K 2023-03-29 · proof |
| Total liabilities | $115 million | $24.9 million | +362.1% | 10-K 2023-03-29 · proof |
| Cash and cash equivalents | $44 million | $78.2 million | -43.7% | 10-K 2023-03-29 · proof |
- What was Provention Bio, Inc.'s revenue in fiscal 2022?
- Provention Bio, Inc. reported revenue of $12.9 million for fiscal 2022 (the year ended Dec 31, 2022), against $1.4 million the year before (+824.4%). Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What was Provention Bio, Inc.'s operating income in fiscal 2022?
- Provention Bio, Inc. reported operating income of -$128.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$115.6 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What was Provention Bio, Inc.'s net income in fiscal 2022?
- Provention Bio, Inc. reported net income of -$113.6 million for fiscal 2022 (the year ended Dec 31, 2022), against -$114.4 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What was Provention Bio, Inc.'s cash from operating activities in fiscal 2022?
- Provention Bio, Inc. reported cash from operating activities of -$75.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$95.4 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What was Provention Bio, Inc.'s free cash flow in fiscal 2022?
- Provention Bio, Inc. reported free cash flow of -$76.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$96.3 million the year before. Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What are Provention Bio, Inc.'s total assets?
- As of Dec 31, 2022, Provention Bio, Inc. reported total assets of $236.9 million, against $135.6 million a year earlier (+74.6%). Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What are Provention Bio, Inc.'s total liabilities?
- As of Dec 31, 2022, Provention Bio, Inc. reported total liabilities of $115 million, against $24.9 million a year earlier (+362.1%). Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
- What are Provention Bio, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Provention Bio, Inc. reported cash and cash equivalents of $44 million, against $78.2 million a year earlier (-43.7%). Source: the 10-K filed with the SEC on Mar 29, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1695357&period_type=annual&limit=5"Information only, not investment advice.